Drugs / C7R-EBVSTs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06345027 | Feb 2026 → May 2027 expected | T-cell leukemia, acute myeloid leukemia | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C7R-EBVSTs | “Patients will be enrolled to this study in two treatment groups: C7R-EBVSTs without lymphodepletion (Group A) and C7R-EBVSTs with lymphodepletion (Group B).” NCT06345027 ↗ |
| Route | Intravenous | “injection of C7 R EBV T cells into the vein through an IV line” NCT06345027 ↗ |